J&J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB's party

Johnson & Johnson has presented phase 3 data on nipocalimab in generalized myasthenia gravis (gMG), providing a look at how its $6.5 billion prospect matches up to the approved FcRn rivals from argenx and UCB.